Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest


Narcolepsy and Idiopathic Hypersomnia Therapeutic Areas of Interest
  • Educate on the burden of illness associated with narcolepsy, including cardiovascular comorbidities, cardiometabolic comorbidities and the lifelong management of the disease
  • Educate on the potential impact of sodium content on health and the relevance of this risk to narcolepsy patients
  • Educate on the screening, diagnosis, and management of idiopathic hypersomnia
  • Educate on the screening and diagnosis of narcolepsy in adults and children
  • Educate on the impact of delayed diagnosis of narcolepsy
Excessive Daytime Sleepiness in Obstructive Sleep Apnea (EDS in OSA) Therapeutic Areas of Interest
  • Educate on the prevalence, potential cause and differential diagnosis of EDS in OSA
  • Educate on the need to treat EDS in OSA to include:
    • Impact on cognitive function
    • Quality of life (QOL)
    • Daily functioning
    • Societal burden
  • Educate on appropriate screening tools for EDS in OSA, continued monitoring of sleepiness, and recognition of suboptimal treatment
  • Educate on pharmacotherapy options available for EDS in OSA to include:
    • Efficacy
    • Safety
    • Treatment goals
    • Impact on patient function and QOL

    Hematology and Oncology

    Acute Myeloid Leukemia (AML) Therapeutic Areas of Interest
    • Educate on the role of intensive chemotherapy in the treatment of secondary AML
    • Educate on identification and timely, actionable diagnosis of high risk AML subsets (e.g., AML-MRC, t-AML)
    • Educate on different technologies for the delivery of secondary AML treatments
      • Educate on the treatment of secondary AML to include:
        • Efficacy
        • Safety
        • Impact on QOL
        • Depth of response and real world data
    • Educate on the appropriate management of secondary AML patients in the in-patient and out-patient setting
    • Educate on the adult AML treatment paradigm (e.g., induction, consolidation, maintenance therapy)
    • Educate on clinical and economic burden of secondary AML
    • Educate on the pediatric population including relapsed/refractory AML
    Endothelial Related Complications Therapeutic Areas of Interest
    • Educate on recognition, incidence, risk factors, diagnosis and early intervention of hepatic veno-occlusive disease (VOD)/ Sinusoidal Obstruction Syndrome (SOS)
    • Educate on VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
    • Educate on the pathophysiology and progressive nature of VOD/SOS and other endothelial related complications
    • Educate on the efficacy and safety of current therapies and patient management for the treatment of VOD/SOS
    • Educate on the clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
    • Educate on the efficacy of current therapies and patient management for COVID-19 related ARDS and endotheliitis
    Small Cell Lung Cancer (SCLC) Therapeutic Areas of Interest
    • Educate on treatment options in second-line therapy for small cell lung cancer (SCLC)
    • Educate on current second-line therapies for SCLC to include:
      • Efficacy
      • Safety
      • Mechanism of Action
    • Educate on patient management and safety profiles of SCLC second line therapies
    Acute Lymphoblastic Leukemia (ALL) Therapeutic Areas of Interest
    • Educate on the:
      • Biology of immune response
      • Management of asparaginase hypersensitivity reaction
      • Impact and burden on safety and efficacy
    • Educate on potential safety concerns associated with current clinical mitigation strategies for hypersensitivity reactions
    • Educate on the efficacy and clinical benefits of new asparaginase formulation in ALL
    • Educate on the management of pediatric and adult/young adult ALL with asparaginase (e.g., monitoring, PK, safety, clinical value)
    • Educate on asparaginase inspired protocols in the adult/young adult population
    • Educate on asparaginase therapies beyond ALL

    View our current requests for application.

    Eligible educational grant applicants include the following (not an exhaustive list):

    • Medical Schools
    • Medical Associations/Medical Societies
    • Hospitals/Medical Centers
    • Medical Education Providers

    This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

    In Europe & International (EUR/INT) the system is also accepting requests for goods (such as books, printing, materials, equipment) and services (such as administrative support, personnel and tools).

    The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

    How to Apply

    • Grant requests to support US Medical Education and Medical and Educational Goods and Services (MEGS) for EUR/INT should be submitted using the Jazz Pharmaceuticals Request Management System.
    • All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
    • The system will guide applicants through the process of determining the request type and the required documents for each request.
    • Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
    • All decisions regarding support are at the discretion of Jazz and will be communicated by email.
    • Submission of a request does not guarantee support.
    • For more information, or for questions regarding the status of a grant request, please email